二十二碳六烯酸（DHA）对 DHA-WIN 试验中接受新辅助化疗的乳腺癌女性血浆细胞因子、氧脂素和 TIL（肿瘤浸润淋巴细胞）的影响

Clinical trials on docosahexaenoic acid (DHA) supplementation and immune changes during breast cancer neoadjuvant chemotherapy (NAC) are limited.

This study evaluated the impact of DHA supplementation during NAC on systemic and tumor immune modulation by assessing plasma inflammatory and cardiac damage markers, tumor-infiltrating lymphocyte (TIL) proportions, and n-6- and n-3-derived oxylipins produced in response to an ex vivo immune challenge. Venous blood was collected at baseline, 9, and 15 weeks during NAC from participants in the DHA for Women with Breast Cancer in the Neoadjuvant Setting (DHA-WIN) trial, which compared DHA-enriched algae (4. 4g/day; n=23) with a placebo (n=26) over 18 weeks. Plasma markers were measured using electrochemiluminescence assays. CD4+ and CD8+ TILs were identified in tumor tissue by immunohistochemistry, and oxylipins were quantified in the supernatant of lipopolysaccharide-stimulated peripheral blood mononuclear cells via liquid chromatography-tandem mass spectrometry.

DHA supplementation resulted in greater increases in the plasma cytokines IFN- and TNF- compared to placebo (P-interaction < . 05). In the DHA group, concentrations of these cytokines increased at 15 weeks compared to baseline (P < . 05). No differences were found between groups for other immune markers or the proportion of TILs.

Compared to the placebo, DHA led to an overall increase in total oxylipin concentrations (P < . 05) and higher production of n-6 fatty acid-derived oxylipins, particularly prostanoids, and n-3 fatty acid-derived oxylipins, including 13-HDoHE. These results suggest that DHA may enhance immune responses by promoting an increase in oxylipin and cytokine concentrations, potentially benefiting patients during breast cancer NAC.